Clinical Trial: A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer

U.S., Dec. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07281209) titled 'A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer' on Nov. 19.

Brief Summary: This is a prospective, single-arm, multi-center Phase II clinical trial designed to evaluate the efficacy and safety of neoadjuvant therapy with SHR-A1811 in combination with Adebelimumab in patients with resectable, early-stage non-small cell lung cancer (NSCLC) harboring HER2 alterations.

Study Start Date: Dec., 2025

Study Type: INTERVENTIONAL

Condition: NSCLC

Intervention: DRUG: SHR-A1811 + Adebrelimab

This study evaluates a novel, chemotherapy-free neoadjuvant regimen un...